Aktie A2PEYH ANCHIANO THERAPEUTICS LTD.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen Anchiano Therapeutics Ltd.

Aktien

A2PEYH

US03280X1028

ANCN

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
ANCHIANO THERAPEUTICS LTD. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sale of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits (form 8-K)
DJ Industrial : Wall Street Narrowly Mixed; Data, Fed Rate Meeting in Focus
Anchiano Therapeutics : Shareholders OK Pending Chemomab Merger
Anchiano Therapeutics Ltd.(NasdaqCM:ANCN) dropped from NASDAQ Composite Index
ChemomAb Ltd. completed the acquisition of Anchiano Therapeutics Ltd. in a reverse merger transaction.
Anchiano Announces Shareholder Approval of the Merger with Chemomab and Prices $45.5M Private Financing
ANCHIANO THERAPEUTICS LTD. : Other Events (form 8-K)
ANCHIANO THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)
Anchiano Therapeutics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020
Anchiano Therapeutics Ltd. Auditor Raises 'Going Concern' Doubt
ANCHIANO THERAPEUTICS LTD. : Other Events (form 8-K)
ANCHIANO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Anchiano Therapeutics Ltd. - ANCN
ANCHIANO THERAPEUTICS LTD. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)
Anchiano Therapeutics : Chemomab Plan Merger to Advance Treatment for Fibrosis-Related Diseases
Anchiano Therapeutics : and Chemomab Announce Entry Into Definitive Merger Agreement
Anchiano Therapeutics Ltd. and Chemomab Ltd. Announce Executive Appointments
ChemomAb Ltd. entered into letter of intent to acquire Anchiano Therapeutics Ltd. for for $27.2 million in a reverse merger transaction.
Anchiano Therapeutics Ltd. Reports Earnings Results for the Third Quarter Ended September 30, 2020
ANCHIANO THERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
ANCHIANO THERAPEUTICS LTD. : Change in Directors or Principal Officers (form 8-K)
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2PEYH Aktie
  4. Nachrichten Anchiano Therapeutics Ltd.
  5. Andere Sprachen